Shots:

• The acquisition will integrate AmpTec’s PCR-based mRNA technology with Merck’s expertise in lipids manufacturing- providing combine offering across mRNA value chain
• The deal will expand Merck’s capabilities to develop & manufacture mRNA for use in vaccines- treatments- and diagnostics applicable in COVID-19 and many other diseases. Additionally- AmpTech’s diagnostic business focusing on customized long RNAs and DNAs for IVDs- complements existing Merck’s portfolio
• The addition of AmpTech’s PCR-based technology to Merck allow the companies to offer innovative technologies- products- and services- advancing life-enhancing therapies

 ­ Ref: Merck KGaA | Image: Merck KGaA